CN111479809A - 一种TGF-βRI抑制剂的晶型、盐型及其制备方法 - Google Patents

一种TGF-βRI抑制剂的晶型、盐型及其制备方法 Download PDF

Info

Publication number
CN111479809A
CN111479809A CN201880080169.9A CN201880080169A CN111479809A CN 111479809 A CN111479809 A CN 111479809A CN 201880080169 A CN201880080169 A CN 201880080169A CN 111479809 A CN111479809 A CN 111479809A
Authority
CN
China
Prior art keywords
formula
compound
tgf
degrees
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880080169.9A
Other languages
English (en)
Other versions
CN111479809B (zh
Inventor
吴立方
贺辉君
陆剑宇
丁照中
胡利红
李卫东
施沈一
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfleet Therapeutics Shanghai Inc
Zhejiang Genfleet Therapeutics Co Ltd
Original Assignee
Genfleet Therapeutics Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfleet Therapeutics Shanghai Inc filed Critical Genfleet Therapeutics Shanghai Inc
Publication of CN111479809A publication Critical patent/CN111479809A/zh
Application granted granted Critical
Publication of CN111479809B publication Critical patent/CN111479809B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本发明公开了一种TGF‑βRI抑制剂的晶型、盐型及其制备方法，还包括所述晶型和盐型在制备治疗癌症药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201880080169.9A 2017-12-13 2018-12-13 一种TGF-βRI抑制剂的晶型、盐型及其制备方法 Active CN111479809B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711331447 2017-12-13
CN2017113314477 2017-12-13
PCT/CN2018/120905 WO2019114792A1 (zh) 2017-12-13 2018-12-13 一种TGF-βRI抑制剂的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CN111479809A true CN111479809A (zh) 2020-07-31
CN111479809B CN111479809B (zh) 2021-10-29

Family

ID=66818947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880080169.9A Active CN111479809B (zh) 2017-12-13 2018-12-13 一种TGF-βRI抑制剂的晶型、盐型及其制备方法

Country Status (13)

Country Link
US (1) US11236112B2 (zh)
EP (1) EP3725786B1 (zh)
JP (1) JP7028977B2 (zh)
KR (1) KR102507328B1 (zh)
CN (1) CN111479809B (zh)
AU (1) AU2018383853B2 (zh)
BR (1) BR112020011602A2 (zh)
CA (1) CA3085498C (zh)
DK (1) DK3725786T3 (zh)
ES (1) ES2960412T3 (zh)
PT (1) PT3725786T (zh)
RU (1) RU2750702C1 (zh)
WO (1) WO2019114792A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112759592A (zh) * 2021-02-01 2021-05-07 无锡鸣鹭医药科技有限公司 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法
CN115969801A (zh) * 2023-03-21 2023-04-18 劲方医药科技(上海)有限公司 用于癌症的药物组合物及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112851695A (zh) * 2021-01-27 2021-05-28 复旦大学附属华山医院 甲酰胺类化合物在制备抗脊索肿瘤药物中的应用及试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050659A1 (en) * 2002-11-27 2004-06-17 Eli Lilly And Company Novel compounds as pharmaceutical agents
CN1681501A (zh) * 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的吡唑衍生物
CN103025731A (zh) * 2010-06-29 2013-04-03 梨花女子大学校产学协力团 作为alk5和/或alk4抑制剂的2-吡啶基取代的咪唑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
CN1951939A (zh) * 2001-05-24 2007-04-25 伊莱利利公司 作为药物的新的吡唑衍生物
JP5131990B2 (ja) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤およびその使用方法
AU2010299483B2 (en) * 2009-09-24 2014-08-28 Sun Pharmaceutical Industries Limited Process for the preparation of sorafenib tosylate
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
WO2017215506A1 (zh) 2016-06-13 2017-12-21 南京明德新药研发股份有限公司 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1681501A (zh) * 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的吡唑衍生物
WO2004050659A1 (en) * 2002-11-27 2004-06-17 Eli Lilly And Company Novel compounds as pharmaceutical agents
CN103025731A (zh) * 2010-06-29 2013-04-03 梨花女子大学校产学协力团 作为alk5和/或alk4抑制剂的2-吡啶基取代的咪唑

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112759592A (zh) * 2021-02-01 2021-05-07 无锡鸣鹭医药科技有限公司 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法
CN115969801A (zh) * 2023-03-21 2023-04-18 劲方医药科技(上海)有限公司 用于癌症的药物组合物及其制备方法
CN115969801B (zh) * 2023-03-21 2023-08-25 劲方医药科技(上海)有限公司 用于癌症的药物组合物及其制备方法

Also Published As

Publication number Publication date
US20210079021A1 (en) 2021-03-18
PT3725786T (pt) 2023-10-17
US11236112B2 (en) 2022-02-01
WO2019114792A1 (zh) 2019-06-20
AU2018383853A1 (en) 2020-07-30
ES2960412T3 (es) 2024-03-04
CA3085498A1 (en) 2019-06-20
EP3725786B1 (en) 2023-08-23
EP3725786A1 (en) 2020-10-21
BR112020011602A2 (pt) 2020-12-08
AU2018383853B2 (en) 2021-06-03
CA3085498C (en) 2023-04-18
KR20200106163A (ko) 2020-09-11
EP3725786A4 (en) 2021-04-28
RU2750702C1 (ru) 2021-07-01
JP7028977B2 (ja) 2022-03-02
JP2021506791A (ja) 2021-02-22
CN111479809B (zh) 2021-10-29
DK3725786T3 (da) 2023-11-27
KR102507328B1 (ko) 2023-03-07

Similar Documents

Publication Publication Date Title
CN111479809B (zh) 一种TGF-βRI抑制剂的晶型、盐型及其制备方法
CN112912380B (zh) 一种mek抑制剂的晶型、无定形及其应用
CN114174271B (zh) 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法
CN114269723B (zh) 吡嗪-2(1h)-酮类化合物的d晶型及其制备方法
CN114174270B (zh) 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
CN109369620B (zh) 吡啶类化合物及其制备方法与抗胃癌应用
WO2019114741A1 (zh) 作为Akt抑制剂的盐型及其晶型
CN108794398B (zh) 具有荧光的选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN112110829A (zh) 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途
WO2020192637A1 (zh) 固体形式的brd4抑制剂化合物及其制备方法与应用
CN116171156A (zh) 含嘧啶基团的三并环类化合物的盐型、晶型及其制备方法
TWI809904B (zh) 一種二甲基取代的噻唑並吡咯酮類化合物的晶型及其製備方法
TWI824626B (zh) Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
CN111148747B (zh) 吡啶并嘧啶类化合物的盐型和晶型及其制备方法
WO2023185869A1 (zh) 一种吡咯并杂环类衍生物的富马酸盐的晶型及其制备方法
WO2023109776A1 (zh) 一种fgfr4抑制剂酸式盐及其制备方法和应用
CN113646313B (zh) 一种a2a受体拮抗剂的盐型、晶型及其制备方法
WO2021047466A1 (zh) 一种p53-MDM2抑制剂的晶型及其制备方法
JP2022530812A (ja) Ｗｅｅ１阻害剤化合物の結晶形及びその応用
CN117567361A (zh) 一类芳基炔类化合物及其制备方法和应用
CN114945565A (zh) 一种吡咯烷基脲衍生物的晶型及其应用
CN113527274A (zh) 喹啉类化合物、其制备方法及用途
CN114907342A (zh) 含氮稠杂环化合物游离碱的多晶型及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Floor 2, 3, 4 and 5, building 8, No. 1206, Zhangjiang Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant after: GENFLEET THERAPEUTICS (SHANGHAI) Inc.

Address before: 201203 No. 63 Building, 1000 Lane, Zhangheng Road, Pudong New Area, Shanghai

Applicant before: GENFLEET THERAPEUTICS (SHANGHAI) Inc.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201201

Address after: Floor 2, 3, 4 and 5, building 8, No. 1206, Zhangjiang Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant after: GENFLEET THERAPEUTICS (SHANGHAI) Inc.

Applicant after: Zhejiang JinFang Pharmaceutical Co.,Ltd.

Address before: Floor 2, 3, 4 and 5, building 8, No. 1206, Zhangjiang Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203

Applicant before: GENFLEET THERAPEUTICS (SHANGHAI) Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025069

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant